{"id":"W4394595366","doi":"10.1016/j.eururo.2024.03.029","title":"Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","year":2024,"lang":"en","type":"editorial","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Pembrolizumab; Urothelial cancer; Oncology; Internal medicine; Bladder cancer; Urology; Gynecology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008222014,0.00394385,0.00502425,0.003782607,0.003040686,0.007171556,0.004323912,0.02309842,0.01840121],"category_scores_gemma":[0.02407358,0.001779891,0.003935914,0.00179182,0.001846315,0.004534952,0.001868515,0.02769413,0.01509499],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005482924,"about_ca_system_score_gemma":0.004118088,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003669537,"about_ca_topic_score_gemma":0.01013751,"domain_scores_codex":[0.9947744,0.001130036,0.0007583199,0.0005105005,0.002417102,0.0004096291],"domain_scores_gemma":[0.983984,0.006590731,0.001683875,0.000389521,0.005043963,0.002307899],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007045572,0.000008345391,0.00001447253,0.0002263539,0.00003323347,0.00006123576,0.000004916658,0.00001671669,0.00003597428,0.0001073174,0.9941177,0.005303214],"study_design_scores_gemma":[0.0004114381,0.00006559891,0.0003126273,0.001098578,0.0002511523,0.000341424,0.00002518521,0.0002064434,0.0001322884,0.0007464284,0.9963796,0.00002935942],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.0000377531,0.01864664,0.0001024536,0.04659009,0.9323512,0.0000318135,0.00009210292,0.00006731001,0.002080664],"genre_scores_gemma":[0.0005310476,0.01048591,0.0001084743,0.04936813,0.928901,0.00004749558,0.00007615431,0.00005222407,0.01042968],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.02309842,"threshold_uncertainty_score":0.06155819,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01013489064885537,"score_gpt":0.2911570393851965,"score_spread":0.2810221487363411,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}